Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLNR | O43193 | 1/20 | 0.65 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | CTSD | P07339 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.65 |
| ▸ | CNR1 | P21554 | 1/20 | 0.65 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.65 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.65 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.46 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.46 |
| ▸ | KCND3 | Q9UK17 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13480514 | 0.85 | MLNR (0.70) | MLNRABCB11LMNACTSDCYP3A4 | |
| SCHEMBL13361099 | 0.85 | MLNR (0.70) | MLNRABCB11LMNACTSDCYP3A4 | |
| SCHEMBL8231341 | 0.83 | ABCB1 (0.67) | MLNRABCB11LMNACTSDCYP3A4 | |
| SCHEMBL691692 | 0.83 | ABCB1 (0.67) | MLNRABCB11LMNACTSDCYP3A4 | |
| SCHEMBL13140395 | 0.83 | ABCB1 (0.67) | MLNRABCB11LMNACTSDCYP3A4 | |
| SCHEMBL16803020 | 0.83 | ABCB1 (0.67) | MLNRABCB11LMNACTSDCYP3A4 | |
| SCHEMBL12435660 | 0.82 | MLNR (0.60) | MLNRABCB11LMNACTSDCYP3A4 | |
| SCHEMBL8248431 | 0.82 | MLNR (0.60) | MLNRABCB11LMNACTSDCYP3A4 | |
| SCHEMBL12512991 | 0.82 | MLNR (0.60) | MLNRABCB11LMNACTSDCYP3A4 | |
| SCHEMBL12435661 | 0.82 | MLNR (0.60) | MLNRABCB11LMNACTSDCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9127029-B2 | Process for preparation of substantially pure fosamprenavir calcium and its intermediates | LUPIN LIMITED (IN) | 2015-09-08 | — | — | US | disclosed |
| US-8877947-B2 | Process for preparation of substantially pure fosamprenavir calcium and its intermediates | LUPIN LIMITED (IN) | 2014-11-04 | — | — | US | disclosed |
| US-20140256959-A1 | PROCESS FOR PREPARATION OF SUBSTANTIALLY PURE FOSAMPRENAVIR CALCIUM AND ITS INTERMEDIATES | LUPIN LIMITED (IN) | 2014-09-11 | — | — | US | disclosed |
| US-20130174651-A1 | PROCESS FOR PREPARATION OF SUBSTANTIALLY PURE FOSAMPRENAVIR CALCIUM AND ITS INTERMEDIATES | LUPIN LIMITED (IN) | 2013-07-11 | — | — | US | disclosed |
| WO-2012032389-A2 | PROCESS FOR PREPARATION OF SUBSTANTIALLY PURE FOSAMPRENAVIR CALCIUM AND ITS INTERMEDIATES | LUPIN LIMITED (IN) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256959-A1 | PROCESS FOR PREPARATION OF SUBSTANTIALLY PURE FOSAMPRENAVIR CALCIUM AND ITS INTERMEDIATES | PLCB3, ITPR3, ITPR2 | MLNR 2161/4885ABCB11 3996/4885LMNA 2901/4885 |
| US-20130174651-A1 | PROCESS FOR PREPARATION OF SUBSTANTIALLY PURE FOSAMPRENAVIR CALCIUM AND ITS INTERMEDIATES | PLCB3, ITPR3, ITPR2 | MLNR 2161/4885ABCB11 3996/4885LMNA 2901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.